Comparison between liposomal formulations of amphotericin B

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Lipid-based Formulations

Background:

• Commercial amphotericin B lipid products have demonstrated clinical success.
• Generic formulations of liposomal amphotericin B are being developed to improve healthcare accessibility and reduce costs.
• Liposomes serve as critical carriers for amphotericin B, mitigating its inherent toxicity.

Purpose of the Study:

• To highlight the importance of bioequivalence studies for generic liposomal amphotericin B.
• To emphasize the need for controlled manufacturing processes in ensuring therapeutic efficacy.
• To underscore the potential variability in generic liposomal products.

Main Methods:

• Comparative analysis of different liposomal amphotericin B formulations.
• Assessment of in vitro and in vivo characteristics.
• Evaluation of chemical composition and manufacturing processes.

Main Results:

• Variations in size, toxicity, and efficacy were observed between different liposomal amphotericin B products.
• Dissimilarities were noted even for products with similar chemical compositions but different production methods.
• Manufacturing processes significantly impact the final product's characteristics.

Conclusions:

• Establishing rigorous bioequivalence testing is essential for liposomal drug products.
• Ensuring uniformity in therapeutic index requires strict control over formulation and manufacturing.
• Generic liposomal amphotericin B must demonstrate comparability to the reference product to ensure patient safety and efficacy.